Assessment of effect of proton pump inhibitor in management of atheroscleroticcardiovascular disease
Not Applicable
- Conditions
- Health Condition 1: I700- Atherosclerosis of aorta
- Registration Number
- CTRI/2023/03/050170
- Lead Sponsor
- Dr Reddys Laboratories Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Patients with documented history of atherosclerotic cardiovascular disease using dual antiplatelet drugs along with PPIs
Exclusion Criteria
Patients with a history of peptic ulcer or gastric or duodenal surgery
Patients with erosive esophagitis and gastric-outlet obstruction
Patients treated with multiple anti-ulcer medications
Patients with severe pulmonary, hepatic, or renal disease
Patients with incomplete records
Patients on anticoagulants other than aspirin plus clopidogrel and on PPIs other than rabeprazole, pantoprazole and esomeprazole.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The outcome of co administration of various currently used <br/ ><br>PPIs with dual antiplatelet therapy in <br/ ><br>patients of atherosclerotic cardiovascular <br/ ><br>disease will be analyzed in terms of percentage of Myocardial infarction Stroke Unstable angina Heart failure Rehospitalization for <br/ ><br>cardiovascular related illness <br/ ><br>Repeat percutaneous coronary <br/ ><br>intervention or coronary artery bypass grafting <br/ ><br>Death Bleeding events Stent thrombosisTimepoint: Baseline to end of 12 months
- Secondary Outcome Measures
Name Time Method The outcome of <br/ ><br>co administration of rabeprazole vs other <br/ ><br>PPIs (pantoprazole, esomeprazole) with <br/ ><br>dual antiplatelet therapy in patients of atherosclerotic cardiovascular <br/ ><br>disease will be analyzed in terms of percentage of Myocardial infarction Stroke Unstable angina Heart failure Rehospitalization for <br/ ><br>cardiovascular related illness <br/ ><br>Repeat percutaneous coronary <br/ ><br>intervention or coronary artery bypass grafting <br/ ><br>Death Bleeding events Stent thrombosisTimepoint: Baseline to end of 12 months